PRAME Expression and Clinical Outcome of Breast Cancer

Overview

Journal Br J Cancer

Specialty Oncology

Date 2008 Jul 24

PMID 18648365

Citations 51

Authors

M T Epping

A A M Hart

A M Glas

O Krijgsman

R Bernards

Affiliations

Soon will be listed here.

Abstract

The tumour antigen PReferentially expressed Antigen of MElanoma (PRAME) is expressed in a variety of malignancies, including breast cancer. We have analysed PRAME gene expression in relation to clinical outcome for 295 primary breast cancer patients. Kaplan-Meier survival curves show a correlation of PRAME expression levels with increased rates of distant metastases and decreased overall patient survival. This correlation existed both for the entire patient group (n=295) and for the subgroup of patients (n=185) who did not receive adjuvant chemotherapy. Multivariable analysis indicated that PRAME is an independent marker of shortened metastasis-free interval in patients who did not receive adjuvant chemotherapy. PRAME expression was associated with tumour grade and negative oestrogen receptor status. We conclude that PRAME expression is a prognostic marker for clinical outcome of breast cancer, independent of traditional clinicopathological markers.

Citing Articles

Prognostic Biomarkers in Breast Cancer via Multi-Omics Clustering Analysis.

Malighetti F, Villa M, Villa A, Pelucchi S, Aroldi A, Cortinovis D Int J Mol Sci. 2025; 26(5).

PMID: 40076569 PMC: 11900291. DOI: 10.3390/ijms26051943.

High-affinity T cell receptor ImmTAC® bispecific efficiently redirects T cells to kill tumor cells expressing the cancer-testis antigen PRAME.

Ribeiro A, Britton-Rivet C, Collins L, Carreira R, Moureau S, Benlahrech A Immunother Adv. 2024; 4(1):ltae008.

PMID: 39659431 PMC: 11631188. DOI: 10.1093/immadv/ltae008.

The Utilization of PRAME in the Diagnosis, Prognosis, and Treatment of Melanoma.

Blount S, Liu X, McBride J Cells. 2024; 13(20.

PMID: 39451258 PMC: 11505691. DOI: 10.3390/cells13201740.

Tumor antigen PRAME is a potential therapeutic target of p53 activation in melanoma cells.

Lee Y, Heo H, Kim N, Park U, Youn H, Moon E BMB Rep. 2024; 57(6):299-304.

PMID: 38835116 PMC: 11214892.

Targeting PRAME for acute myeloid leukemia therapy.

Yang J, Chen M, Ye J, Ma H Front Immunol. 2024; 15:1378277.

PMID: 38596687 PMC: 11002138. DOI: 10.3389/fimmu.2024.1378277.

References

Radich J, Dai H, Mao M, Oehler V, Schelter J, Druker B . Gene expression changes associated with progression and response in chronic myeloid leukemia. Proc Natl Acad Sci U S A. 2006; 103(8):2794-9. PMC: 1413797. DOI: 10.1073/pnas.0510423103. View

Epping M, Wang L, Edel M, Carlee L, Hernandez M, Bernards R . The human tumor antigen PRAME is a dominant repressor of retinoic acid receptor signaling. Cell. 2005; 122(6):835-47. DOI: 10.1016/j.cell.2005.07.003. View

Ikeda H, Lethe B, Lehmann F, Van Baren N, Baurain J, De Smet C . Characterization of an antigen that is recognized on a melanoma showing partial HLA loss by CTL expressing an NK inhibitory receptor. Immunity. 1997; 6(2):199-208. DOI: 10.1016/s1074-7613(00)80426-4. View

Oberthuer A, Hero B, Spitz R, Berthold F, Fischer M . The tumor-associated antigen PRAME is universally expressed in high-stage neuroblastoma and associated with poor outcome. Clin Cancer Res. 2004; 10(13):4307-13. DOI: 10.1158/1078-0432.CCR-03-0813. View

Epping M, Bernards R . A causal role for the human tumor antigen preferentially expressed antigen of melanoma in cancer. Cancer Res. 2006; 66(22):10639-42. DOI: 10.1158/0008-5472.CAN-06-2522. View

Buyse M, Loi S, Veer L, Viale G, Delorenzi M, Glas A . Validation and clinical utility of a 70-gene prognostic signature for women with node-negative breast cancer. J Natl Cancer Inst. 2006; 98(17):1183-92. DOI: 10.1093/jnci/djj329. View

Willenbrock K, Kuppers R, Renne C, Brune V, Eckerle S, Weidmann E . Common features and differences in the transcriptome of large cell anaplastic lymphoma and classical Hodgkin's lymphoma. Haematologica. 2006; 91(5):596-604. View

Doolan P, Clynes M, Kennedy S, Mehta J, Crown J, ODriscoll L . Prevalence and prognostic and predictive relevance of PRAME in breast cancer. Breast Cancer Res Treat. 2007; 109(2):359-65. DOI: 10.1007/s10549-007-9643-3. View

J van t Veer L, Dai H, van de Vijver M, He Y, Hart A, Mao M . Gene expression profiling predicts clinical outcome of breast cancer. Nature. 2002; 415(6871):530-6. DOI: 10.1038/415530a. View

10.

Steinbach D, Viehmann S, Zintl F, Gruhn B . PRAME gene expression in childhood acute lymphoblastic leukemia. Cancer Genet Cytogenet. 2002; 138(1):89-91. DOI: 10.1016/s0165-4608(02)00582-4. View

11.

Li C, Guo M, Borczuk A, Powell C, Wei M, Thaker H . Gene expression in Wilms' tumor mimics the earliest committed stage in the metanephric mesenchymal-epithelial transition. Am J Pathol. 2002; 160(6):2181-90. PMC: 1850829. DOI: 10.1016/S0002-9440(10)61166-2. View

12.

Hughes T, Mao M, Jones A, Burchard J, Marton M, Shannon K . Expression profiling using microarrays fabricated by an ink-jet oligonucleotide synthesizer. Nat Biotechnol. 2001; 19(4):342-7. DOI: 10.1038/86730. View

13.

Steinbach D, Hermann J, Viehmann S, Zintl F, Gruhn B . Clinical implications of PRAME gene expression in childhood acute myeloid leukemia. Cancer Genet Cytogenet. 2002; 133(2):118-23. DOI: 10.1016/s0165-4608(01)00570-2. View

14.

van de Vijver M, He Y, Vant Veer L, Dai H, Hart A, Voskuil D . A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med. 2002; 347(25):1999-2009. DOI: 10.1056/NEJMoa021967. View

15.

Paydas S, Tanriverdi K, Yavuz S, Disel U, Baslamisli F, Burgut R . PRAME mRNA levels in cases with acute leukemia: clinical importance and future prospects. Am J Hematol. 2005; 79(4):257-61. DOI: 10.1002/ajh.20425. View

16.

Boon K, Edwards J, Siu I, Olschner D, Eberhart C, Marra M . Comparison of medulloblastoma and normal neural transcriptomes identifies a restricted set of activated genes. Oncogene. 2003; 22(48):7687-94. DOI: 10.1038/sj.onc.1207043. View

17.

Bernards R, Weinberg R . A progression puzzle. Nature. 2002; 418(6900):823. DOI: 10.1038/418823a. View

18.

Neumann E, Engelsberg A, Decker J, Storkel S, Jaeger E, Huber C . Heterogeneous expression of the tumor-associated antigens RAGE-1, PRAME, and glycoprotein 75 in human renal cell carcinoma: candidates for T-cell-based immunotherapies?. Cancer Res. 1998; 58(18):4090-5. View